Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

On Monday, 17 November 2025, Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) presented at the Jefferies London Healthcare Conference 2025. The company highlighted its robust financial performance and ...

Kiniksa Pharmaceuticals (KNSA) just delivered its third quarter earnings, highlighting an impressive jump in ARCALYST revenue and a shift to positive net income. The company also updated its guidance, ...

Sanj Patel, CEO & Chairman of the Board, stated that "Year-to-date, in 2025, we've continued to execute and meaningfully advance our commercial business and clinical development portfolio." He ...

- ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth - - ARCALYST 2025 expected net product revenue raised to $670 - $675 million - - KPL-387 ...

Kiniksa Pharmaceuticals Ltd (KNSA) reported significant growth in its third-quarter earnings for 2025, driven by robust sales of its flagship product, ARCALYST. The company raised its full-year net ...

- ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth - - ARCALYST 2025 expected net product revenue raised to $670 - $675 million - LONDON, ...

LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases ...

Investing.com - TD Cowen has reiterated its Buy rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a price target of $60.00, citing impressive commercial execution of its Arcalyst drug. The stock, ...

Investing.com - TD Cowen has initiated coverage of Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy rating and a $60.00 price target, citing the company’s positive cash flow and growth potential for ...

Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...